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Abstract
Background: Patients with asthma demonstrate circadian variations in the airway inflammation
and lung function. Pinealectomy reduces the total inflammatory cell number in the asthmatic rat
lung. We hypothesize that melatonin, a circadian rhythm regulator, may modulate the circadian
inflammatory variations in asthma by stimulating the chemotaxins expression in the lung epithelial
cell.
Methods: Lung epithelial cells (A549) were stimulated with melatonin in the presence or absence
of TNF-α(100 ng/ml). RANTES (Regulated on Activation Normal T-cells Expressed and Secreted)
and eotaxin expression were measured using ELISA and real-time RT-PCR, eosinophil chemotactic
activity (ECA) released by A549 was measured by eosinophil chemotaxis assay.
Results: TNF-α increased the expression of RANTES (307.84 ± 33.56 versus 207.64 ± 31.27 pg/
ml of control, p = 0.025) and eotaxin (108.97 ± 10.87 versus 54.00 ± 5.29 pg/ml of control, p =
0.041). Melatonin(10-10 to 10-6M) alone didn't change the expression of RNATES (204.97 ± 32.56
pg/ml) and eotaxin (55.28 ± 6.71 pg/ml). However, In the presence of TNF-α (100 ng/ml), melatonin
promoted RANTES (410.88 ± 52.03, 483.60 ± 55.37, 559.92 ± 75.70, 688.42 ± 95.32, 766.39 ±
101.53 pg/ml, treated with 10-10, 10-9, 10-8, 10-7,10-6M melatonin, respectively) and eotaxin (151.95
± 13.88, 238.79 ± 16.81, 361.62 ± 36.91, 393.66 ± 44.89, 494.34 ± 100.95 pg/ml, treated with 10-
10, 10-9, 10-8, 10-7, 10-6M melatonin, respectively) expression in a dose dependent manner in A549
cells (compared with TNF-α alone, P < 0.05). The increased release of RANTES and eotaxin in
A549 cells by above treatment were further confirmed by both real-time RT-PCR and the ECA
assay.
Conclusion: Taken together, our results suggested that melatonin might synergize with pro-
inflammatory cytokines to modulate the asthma airway inflammation through promoting the
expression of chemotaxins in lung epithelial cell.
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Backgound
Eosinophils are known to be the important effector cells
in asthmatic airway inflammations[1]. Previous studies
have demonstrated that eosinophils are accumulated in
the peripheral blood, the bronchoalveolar lavage fluid,
and the airway of the asthmatic patients or the allergen-
sensitized animals[2]. Eosinophil trafficking is regulated
by a wide variety of chemotactic factors[3]. Eotaxin and
RANTES (Regulated on Activation Normal T-cells
Expressed and Secreted) are C-C chemotaxins that can
recruit eosinophils to the airway in asthma[4]. A variety of
tissues and cell types, including lung epithelial cell, pro-
duce eotaxin and RANTES which play an important role in
airway[5].
Pro-inflammatory cytokines such as tumor necrosis factor
(TNF) and interleukin (IL)-1 are released in the early stage
of allergic inflammation. In endothelial and epithelial
cells, TNF-α induces an influx of eosinophils into tissues
through the increased expression of adhesion mole-
cules[6,7]. Although eotaxin and RANTES tend to be
expressed constitutively in several cell types, their expres-
sion may also be regulated in response to TNF-α in other
cell lines[8].
Melatonin(N-acetyl-5-methoxytryptamine) is a key regu-
lator of circadian rhythm homeostasis in humans[9,10]. It
also appears to have an important immunomodulatory
effect in allergic diseases[11,12]. Melatonin promotes the
cytokine production in the peripheral blood mononu-
clear cell. Pinealectomized rats sensitized to ovalbumin
demonstrated that pinealectomy significantly reduces the
inflammatory cell counts in the bronchoalveolar lavage
fluid after ovalbumin challenge, and that melatonin
administration to pinealectomized rats restores the ability
of inflammatory cells to migrate to the bronchoalveolar
fluid. Those results suggest that melatonin may modulate
the expression of chemotaxins in airway epithelial or
endothelial cells[13].
The circadian variations of lung function in nocturnal
asthma are associated with the increased airway inflam-
mation during night. As a key regulator in human circa-
dian rhythm homeostasis as well as an
immunomodulator in allergic diseases, melatonin may
regulate the circadian airway inflammation in asthma
through modulating the expression of chemotaxins in the
airway epithelial cells.
In order to test this hypothesis, we conducted the present
study to answer two questions. First, whether melatonin is
able to up-regulate RANTES and eotaxin expression in the
lung epithelia cell line-A549. Second, what is the combi-
natory effect of melatonin and TNF-α on RANTES and
eotaxin expression and whether this effect increases the
eosinophils chemotactic activity (ECA) released in A549.
The answers to these questions might provide new
insights into the pathophysiology of asthma.
Methods
This study was approved by the medical ethics committee
of the West China Hospital of Sichuan University.
Informed consents were obtained from all subjects in the
study.
Cell Culture
A549 cells, human type II-like epithelial lung cells, were
obtained from ATCC (Manassas, VA, USA). The cells were
cultured in tissue flasks incubated in 100% humidity and
5% CO2 at 37°C in DMEM medium (GIBCO BRL, Grand
Island, NY) supplemented with 10% heat-inactived fetal
bovine serum (GIBCO BRL) and penicillin-streptomycin
(50 µg/ml, GIBCO BRL), at 1 × 106 cells/ml. A549 cells
were then plated onto 6-well, flat-bottom tissue culture
plates (Becton Dickinson and Co., NJ, USA) at a density of
1 × 106 cells/ well in DMEM medium. The medium was
changed every 2 d until the cells became confluent and
then the cells were used for the experiments.
Cytokine Assays
As IL-1β and TNF-α have similar effect on the expression
of many chemotaxins[14,15], we chose TNF-α as the rep-
resentative pro-inflammatory cytokines in the asthmatic
lung in this study. After the cells became confluent, the
medium was changed to serum-free DMEM medium for
12 h. A549 cells were then exposed to increasing concen-
trations of melatonin (10-10, 10-9, 10-8, 10-7, 10-6M, the
physiology concentration are 10-9 to 10-7 M during day
and night[16]) (Sigma, St. Louis, MO, USA) and TNF-α
(100 ng/ml) (Sigma), for 12 h. The cells were also stimu-
lated with a combination of melatonin (10-10, 10-9, 10-8,
10-7, 10-6M) and TNF-α (100 ng/ml). The epithelial cell
layers were then washed three times with Hanks' balanced
salt solution (GIBCO BRL) and incubated for 48 h. Cell-
free culture supernatants were collected. RANTES and
eotaxin were assayed using enzyme-linked immunosorb-
ent assay (ELISA) kits according to the instructions of the
manufacturers. Assay kits for RANTES and eotaxin were
purchased from R&D Systems (Minneapolis, MN, USA),
and the minimum detectable concentration of RANTES
and eotaxin was 5 pg/ml. Experiments were performed at
least three times with the similar results.
RNA extraction and real-time PCR
RNA extraction and real-time PCR were performed as pre-
viously described[17,18]. After the cells became conflu-
ent, the medium was changed to fetal bovine serum free
DMEM medium for 12 h. A549 cells were then exposed to
different concentrations of melatonin, together with or
without TNF-α (100 ng/ml) (Sigma) for 12 h. TotalRespiratory Research 2004, 5:20 http://respiratory-research.com/content/5/1/20
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cellular RNA was extracted using an acid guanidinium-
phenol-chloroform method (Trizol; GIBCO BRL). RNA
integrity was confirmed by electrophoresis on 1% agarose
gels and ethidium bromide staining. Total cellular RNA, 1
µg, was reverse transcribed at 37°C for 70 min in 20 µl
containing 2.5 U Superscript-II reverse transcriptase
(GIBCO BRL); 10 mM dithiothreitol, 1 mM each of
deoxyadenosine triphosphate (dATP), deoxythymidine
triphosphate (dTTP), deoxycytidine triphosphate (dCTP),
and deoxyguanidine triphosphate (dGTP); and 5 µg/ml
oligo-dT primer (Pharmacia, Piscataway, NJ). Reactions
were stopped by heat inactivation for 10 min at 85°C.
Primers for human eotaxin, RANTES and β-actin were syn-
thesized, HPLC purified as GIBCO BRL Custom Primers
(Hong Kong, China). Primer sequences were as follows:
Eotaxin: upstream primer: 5'- ACA TGA AGG TCT CCG
CAG CAC TTC -3', downstream primer: 5'- TTG GCC AGG
TTA AAG CAG CAG GTG -3'. RANTES upstream primer:
5'- GGC ACG CCT CGC TGT CAT CCT CA-3'; downstream
primer: 5'- CTT GAT GTG GGC ACG GGG CAG TG-3'. β-
actin upstream primer: 5'- AAG AGA GGC ATC CTC ACC
CT -3',downstream primer 5'- TAC ATG GCT GGG GTG
TTG AA -3'. Real-time PCR was performed on the ABI
Prism 7700 sequence detection system (PE Applied Bio-
systems) by using SYBR green (Roche Diagnostics, Somer-
ville, NJ) as a dsDNA-specific binding dye. The PCR were
cycled 40 times after initial denaturation (95°C, 2 min)
with the following parameters: denaturation, 95°C, 15s;
and annealing and extension, 60°C, 1 min. The threshold
cycle (CT) was recorded for each sample to reflect the
mRNA expression levels. The fold changes of eotaxin or
RANTES gene expression were calculated as previously
described[18].
Eosinophil Chemotaxis Assay
Eosinophil chemotaxis assay was performed as described
previously[19]. Briefly, eosinophils were isolated from the
peripheral blood of three healthy donors by negatively
selected with immunomagnetic beads. Erythrocytes in
venous peripheral blood were removed by hypotonic
lysis. Neutrophils and mononuclear cells were depleted
with anti-CD16 and anti-CD3 immunomagnetic beads
(Miltenyi Biotec GmbH, Bergisch Gladbach, Germany).
Eosinophils were stained with Randolph's stain and
counted in a hemocytometer. Cytospins of each prepara-
tion were stained with Diff-Quik (International Reagent
Corp., Green Cross, Osaka, Japan). The mean percentage
of the eosinophil purity was 98.0 ± 0.3%. The viability
measured by trypan blue exclusion was consistently
greater than 95.0%. Eosinophil chemotaxis assay was
measured by the Boyden's blind-well chamber technique
using a 48-well, multiwell chamber (NeuroProbe Inc.,
Bethesda, MD). The bottom wells of the chamber were
filled with 26.5 µl of the A549 cell supernatant stimulated
by various chemicals, as described previously, in tripli-
cate. A polycarbonate filter with a pore size of 5 µm
(Nucleopore, Pleasanton, CA) was placed over the bottom
wells, and isolated eosinophils were placed into each of
the top wells. The chambers were then incubated at 37°C,
5% CO2 for 90 min. After incubation, eosinophils in the
top wells were removed by scraping. The filter was then
stained with Diff-Quik. Eosinophil chemotactic activity
(ECA) is shown as the total number of migrated eosi-
nophils counted in 10 high-power fields under a light
microscope (Olympus, Lake Success, NY) at × 400
magnification.
Data analysis
Data were expressed as means ± SD. Differences between
groups were assessed by one-way ANOVA followed by the
LDS significant difference test. A value of p < 0.05 was
considered statistically significant.
Results
Effect of TNF-α and melatonlin on RANTES and eotaxin 
released from A549 cells
RANTES released from A549 cells increased significantly
when the cells incubated with TNF-α(100 ng/ml). Mela-
tonin alone didn't have this effect on A549 in dose
from10-10 to 10-6M. However, TNF-α induced RANTES
release in A549 increased significantly by incubation with
melatonin (from10-10  to 10-6M). Similarly, eotaxin
released from A549 cells also increased significantly when
the cells incubated with TNF-α; Melatonin alone had no
effect on eotaxin released from A549 at dose range
from10-10 to 10-6M. However, eotaxin released from A549
increased significantly when the cells incubated with
melatonin and TNF-α (Figure 1).
Effect of TNF-α and melatonlin on the expression of 
RANTES and eotaxin in A549 cells
To determine whether the production of RANTES and
eotaxin is accompanied by the transcription of the corre-
sponding genes, we used real-time RT-PCR to examine
RANTES and eotaxin mRNA expression in A549 cells.
A549 were stimulated with melatonin (10-10, 10-9, 10-8,
10-7, 10-6M) and TNF-α (100 ng/ml). Melatonin alone did
not change the RANTES and eotaxin mRNA expression in
A549. TNF-α can promote the RANTES and eotaxin
expression in A549 cells. When stimulated with TNF-α,
melatonin synergistically increased the RANTES and
eotaxin expression in a dose dependent manner (Fig 2).
Effect of TNF-α and melatonlin on eosinophil chemotactic 
activity (ECA) released by A549 Cells
When stimulated with TNF-α(100 ng/ml), ECA released
by A549 cells increased significantly. Melatonin (from10-
10 to 10-6M) alone didn't have this effect. When stimulated
with TNF-α (100 ng/ml) and melatonin, ECA releasedRespiratory Research 2004, 5:20 http://respiratory-research.com/content/5/1/20
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increased in A549 cells in a dose dependent manner (Fig
3).
Discussion
In this study, we examined the RANTES and eotaxin pro-
tein level and the gene expression in A549 in response to
TNF-α and melatonin stimulation using ELISA and real-
time RT-PCR. We also measured the ECA released by A549
in response to TNF-α and melatonin stimulation. Unex-
pected, we found that the eotaxin and RANTES protein
level and gene expression in A549 cells were unchanged
when treated with melatonin alone, and the ECA released
by A549 remained unchanged too. However, when A549
cells co-stimulated with melatonin and TNF-α, eotaxin
and RANTES released from the cells increased in a mela-
tonin dose dependent manner. The gene expression of
eotaxin and RANTES, and the ECA also increased at the
same time. This result support our hypothesis that mela-
tonin play an important role in airway inflammation
through up-regulation of the eotaxin and RANTES expres-
sion in lung epithelial cell when the cells stimulated with
pro-inflammatory cytokines.
The pro-inflammatory characteristics of TNF-α have been
documented extensively. Numerous studies have demon-
strated that these attributes contribute to the
RANTES and eotaxin released from A549 cells Figure 1
RANTES and eotaxin released from A549 cells. Melatonin(10-6M) alone did not change RANTES and eotaxin released 
from A549 cells. However, it (from10-10 to 10-6M) promoted RANTES and eotaxin released from A549 cells in a dose depend-
ent manner when co-stimulated with TNF-α (100 ng/ml). * and **, p < 0.05 and 0.01, compared with control and melatonin 
alone (pg/ml, n = 3). $ and #, p < 0.05 and 0.01, compared with TNF-α alone (pg/ml, n = 3).Respiratory Research 2004, 5:20 http://respiratory-research.com/content/5/1/20
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inflammatory conditions present in airways of asthmatic
subjects. TNF-α has been shown to activate the inflamma-
tory cells, up-regulate the adhesion molecules on
endothelium and circulating leukocytes, increase the pro-
duction of chemotaxins[20], the bronchial responsive-
ness. TNF-α is expressed primarily by the alveolar cells
and tissue macrophages, mast cells, and bronchial epithe-
lial cells. Additionally, in most other airway cell systems
studied, conditions simulating an inflammatory state
result in expression of TNF-α. Thus, it is not surprising
that TNF-α concentration is higher in the bronchoalveolar
lavage fluid from symptomatic asthmatics compared with
normal control subjects[21]. In this study, we found that
TNF-α could promote the RANTES and eotaxin produc-
tion in A549 and melatonin further exaggerated this effect
of TNF-α.
Lung function in a healthy individual varies in a circadian
rhythm, with the peak lung function occurring near 4:00
PM (1600 hours) and the minimal lung function
occurring near 4:00 AM (0400 hours). An episode of noc-
turnal asthma is characterized by an exaggeration in this
normal variation in lung function from daytime to night-
time, with diurnal changes in the pulmonary function
RANTES and eotaxin mRNA expression in A549 cells Figure 2
RANTES and eotaxin mRNA expression in A549 cells. Melatonin(10-6M) alone did not change the RANTES and eotaxin 
mRNA expression in A549 cells. TNF-α (100 ng/ml) could promote the RANTES and eotaxin expression in A549 cells. Mela-
tonin (from10-10 to 10-6M) increased the RANTES expression of A549 cell in a dose dependent manner when co-stimulated 
with TNF-α(100 ng/ml). **, p < 0.01, compared with control and melatonin alone (n = 3). #, p < 0.01, compared with TNF-α 
alone (n = 3).Respiratory Research 2004, 5:20 http://respiratory-research.com/content/5/1/20
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generally of > 15%. A recent study showed that the circa-
dian variability in pulmonary function in asthma was
related to changes in the airway eosinophils recruitment
and activation[22]. Although the molecular mechanism
responsible for the selective infiltration of eosinophils
into the inflamed tissue in asthma has not been eluci-
dated, chemotaxin may play an important role in this
process. Eotaxin is a chemotaxin that binds with high
affinity and specificity to the chemotaxin receptor CCR3
and plays an important role in the pathogenesis of allergic
disease. RANTES, a C-C chemotaxin, was initially shown
to be chemoattractant for T cells and monocytes but has
subsequently been shown to be a potent eosinophil che-
moattractant[23,24]. In other studies, an up-regulation of
RANTES message was observed in the airways of asth-
matic patients[25], and increased levels of RANTES have
been detected in the nasal aspirates of children with the
viral exacerbation of asthma[26], suggesting an important
role for RANTES in this process. From the result of our
study, together with the studies above, we can infer that
melatonin, the most important circadian rhythm regula-
tor, may also regulate the asthma airway inflammation by
up-regulating the expression of eotaxin and RANTES in
the airway epithelium in inflammatory status of asthma.
Eosinophil chemotactic activity (ECA) released from A549 cells Figure 3
Eosinophil chemotactic activity (ECA) released from A549 cells. Melatonin (10-6M) alone did not change the ECA 
released from A549 cells. TNF-α (100 ng/ml) could increase the ECA released from A549 cells. Melatonin (from10-10 to 10-6M) 
increased the ECA released from A549 cell in a dose dependent manner when co-stimulated with TNF-α(100 ng/ml). **, p < 
0.01, compared with control and melatonin alone (n = 3). #, p < 0.01, compared with TNF-α alone (n = 3).Respiratory Research 2004, 5:20 http://respiratory-research.com/content/5/1/20
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RANTES and eotaxin expression are regulated by two
important transcriptional factors: active protein-1 (AP-1)
and nuclear factor kappa B(NFκB). Benis et al[27] found
that melatonin could suppress the activation of NFκB and
AP-1. Although NFκB and AP-1 could up-regulate the
expression of many pro-inflammatory cytokines and
chemotaxins, other transcriptional factors also could be
involved in the regulation of RANTES and eotaxin. Further
studies are needed to elucidate the mechanism of how
melatonin regulates the transcription of these
chemotaxins.
The role of melatonin as an immunomodulator is poorly
understood and, in some cases, contradictory results have
been reported. For example, Shafer's study showed that
melatonin has no effect on the activity of stimulated mac-
rophages[28]. However, pinealectomy of rats significantly
reduces airway inflammation after ovalbumin inhala-
tional challenge, and melatonin administration to the
pinealectomized rats seems to restore the airway inflam-
mation, which further supports the pro-inflammatory
effect of melatonin. In addition, up-regulation of the gene
expression of transforming growth factor-β(TGF-β), mac-
rophage-colony stimulating factor (M-CSF), TNF-α and
stem cell factor (SCF) in peritoneal exudate cells, and up-
regulation of the gene expression of IL-1β, M-CSF, TNF-α,
interferon-γ (IFN-γ) and SCF in splenocytes, were
observed in male C57 mice received 10 consecutive daily
intraperitoneal injections of melatonin[12]. Further
research should be directed at evaluating the mechanism
of melatonin regulating the transcription of those kinds of
cytokines.
Conclusion
Melatonin alone did not change eotaxin and RANTES pro-
tein level and gene expression in A549 cells, and had no
effect on ECA released by A549 cells. However, when
A549 cells were stimulated with melatonin, together with
TNF-α, the mRNA expression and protein release of
eotaxin and RANTES increased significantly. This result
suggested that combined with pro-inflammatory
cytokines, melatonin may play a role in the airway inflam-
mation through up-regulation of the eotaxin and RANTES
expression in the lung epithelial cells.
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